In a surprise decision that could represent a shift in standards for assessing the effectiveness of cancer medicines, the FDA clears Avastin for use in treating breast cancer. The federal agency is judging the drug’s effectiveness based on measurements of tumor growth, not patient survival.
Original post by Associated Press
0 Responses to “FDA Breast Cancer Drug Approval Prompts Mixed Reaction”